CA
CALZF.US PolyNovo Limited
- Market cap
- USD 446M
- P/E
- 64.5x
- P/B
- 7.16x
- ROE
- 8.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CALZF.US undervalued?
Graham numberThe Graham number of PolyNovo Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PolyNovo Limited fundamental analysis
No fundamental analysis for PolyNovo Limited yet.
PolyNovo Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PolyNovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device p…
Full company profilePolyNovo Limited financial statements
PolyNovo Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 3.62M | 6.55M | 14.0M | 22.2M | 29.2M | 41.4M | 65.2M | 103M | 127M | 144M |
| Gross Profit | 2.20M | 2.12M | 9.50M | 20.5M | 27.6M | 39.2M | 60.8M | 97.7M | 122M | 46.9M |
| Operating Income | -5.15M | -7.09M | -4.56M | -4.14M | -3.15M | -257K | -6.19M | 1.16M | 4.48M | 10.5M |
| EBITDA | -5.59M | -6.57M | -3.88M | -3.27M | -3.24M | 780K | -2.52M | 4.53M | 11.3M | 13.9M |
| Net Income | -5.01M | -5.97M | -3.19M | -4.19M | -4.61M | -1.19M | -4.93M | 5.26M | 13.2M | 7.33M |
| EPS | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 | 0.01 | 0.02 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 12.1M | 29.8M | 28.2M | 37.9M | 38.3M | 35.0M | 92.6M | 109M | 127M | 132M |
| Total Liabilities | 1.24M | 1.36M | 2.13M | 14.0M | 16.0M | 17.3M | 27.2M | 36.6M | 44.1M | 41.7M |
| Shareholders' Equity | 10.8M | 28.5M | 26.1M | 23.8M | 22.4M | 17.7M | 65.4M | 72.1M | 83.3M | 90.6M |
| Cash & Short-term Investments | 5.55M | 22.2M | 14.0M | 11.7M | 7.74M | 6.15M | 46.9M | 46.0M | 33.6M | 35.4M |
| Total Debt | - | - | - | 10.0M | 10.00M | 11.0M | 16.0M | 15.4M | 17.1M | 17.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.16M | -6.88M | -3.37M | -403K | -249K | -2.06M | -5.93M | 3.68M | 3.15M | 23.2M |
| Capital Expenditure | 582K | 220K | 6.52M | 8.87M | 3.57M | 492K | 1.53M | 2.90M | 13.9M | 13.8M |
| Free Cash Flow | -5.74M | -7.10M | -9.89M | -9.27M | -3.82M | -2.55M | -7.46M | 786K | -10.8M | 9.44M |
| Ratios | ||||||||||
| ROE | -46.3% | -21.0% | -12.2% | -17.6% | -20.6% | -6.7% | -7.5% | 7.3% | 15.9% | 8.1% |
| ROA | -41.5% | -20.0% | -11.3% | -11.1% | -12.0% | -3.4% | -5.3% | 4.8% | 10.4% | 5.5% |
| Net Profit Margin | -138.3% | -91.2% | -22.7% | -18.9% | -15.8% | -2.9% | -7.5% | 5.1% | 10.4% | 5.1% |
| Debt to Equity | - | - | - | 0.42x | 0.45x | 0.62x | 0.25x | 0.21x | 0.21x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PolyNovo Limited dividends
PolyNovo Limited has not paid dividends in the last 10 fiscal years.
Who owns PolyNovo Limited
- Insiders 9.97%
- Institutions 30.60%
- Public & others 59.43%
- Shares outstanding 691M
- Free float 601M
PolyNovo Limited company profile
- Company name
- PolyNovo Limited
- Ticker
- CALZF.US
- ISIN
- AU000000PNV0
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 301
- Fiscal year end
- June
- Address
- 320 Lorimer Street, Port Melbourne, VIC, Australia, 3207
- Phone
- 61 3 8681 4050
- Website
- polynovo.com
About PolyNovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
PolyNovo Limited management
8- Mr. Bruce Peatey M.B.A.Chief Executive Officer
- Mr. Jan-Marcel Gielen C.A.CFO & Company Secretary
- Dr. Marthe D'OmbrainChief Scientific Officer
- Ms. Amy DemediukCompany Secretary & General Counsel
- Ms. Kimberley AxonChief People Officer
- Mr. Edward GraubartPresident of North America
- Ms. Allison Myers B.Sc.Chief Quality & Regulatory Affairs Officer
- Mr. Tyson Parker M.B.A.Chief Manufacturing & Supply Chain Officer